Anebulo Pharmaceuticals Inc
ANEB2.700USD
-0.150-5.26%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
2.700USD+2.700After-hours (ET)
110.93MMarket Cap
LossP/E TTM
Anebulo Pharmaceuticals Inc
2.700
-0.150-5.26%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Operating expenses
13.70%1.89M
-6.24%2.59M
-5.17%2.41M
-46.26%1.34M
-41.89%1.66M
-27.61%2.76M
-2.62%2.54M
7.26%2.49M
52.37%2.86M
255.99%3.81M
67.99%2.61M
-6.41%2.33M
240.43%1.88M
--1.07M
--1.55M
--2.48M
--552.13K
R&D expenses
-14.70%638.32K
14.86%1.22M
3.51%1.31M
-67.00%467.71K
-31.30%748.34K
-43.17%1.06M
3.80%1.27M
26.74%1.42M
19.01%1.09M
778.16%1.87M
71.13%1.22M
-38.11%1.12M
235.25%915.36K
--212.94K
--715.10K
--1.81M
--273.04K
Depreciation, depletion, and amortization
----
----
----
----
----
----
--0.00
----
--0.00
--0.00
--0.00
----
--0.00
--0.00
--0.00
--0.00
--0.00
Operating profit
-13.70%-1.89M
6.24%-2.59M
5.17%-2.41M
46.26%-1.34M
41.89%-1.66M
27.61%-2.76M
2.62%-2.54M
-7.26%-2.49M
-52.37%-2.86M
-255.99%-3.81M
-67.99%-2.61M
6.41%-2.33M
-240.43%-1.88M
---1.07M
---1.55M
---2.48M
---552.13K
Net non-operating interest income (expenses)
Non-operating interest income
50.19%102.26K
-90.64%7.07K
-52.89%26.01K
-45.66%50.22K
--68.08K
--75.52K
--55.20K
1160.32%92.41K
----
----
----
618.82%7.33K
----
----
----
--1.02K
----
Non-operating interest expense
310.72%245.18K
87.50%59.70K
--59.70K
--59.70K
--59.70K
--31.84K
----
----
----
----
----
--0.00
-100.00%0.00
--0.00
----
--0.00
--3.70K
Special income (expenses)
----
----
----
----
----
----
----
----
----
----
----
100.00%0.00
----
----
----
---26.63M
----
Other non-operating income (expenses)
15370.83%359.08K
30024.24%177.75K
3100.72%245.08K
99.87%-124.00
-96.49%2.32K
95.70%-594.00
3511.79%7.66K
-1939.17%-93.60K
1995.46%66.07K
-639.97%-13.83K
-86.13%212.00
-241.52%-4.59K
--3.15K
---1.87K
--1.53K
---1.34K
----
Income before tax
-1.37%-1.68M
9.36%-2.46M
11.29%-2.20M
45.91%-1.35M
40.90%-1.65M
28.99%-2.72M
5.02%-2.48M
-7.44%-2.50M
-49.11%-2.80M
-256.66%-3.83M
-68.14%-2.61M
92.02%-2.32M
-237.60%-1.88M
---1.07M
---1.55M
---29.11M
---555.83K
Income tax
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
Income after tax
-1.37%-1.68M
9.36%-2.46M
11.29%-2.20M
45.91%-1.35M
40.90%-1.65M
28.99%-2.72M
5.02%-2.48M
-7.44%-2.50M
-49.11%-2.80M
-256.66%-3.83M
-68.14%-2.61M
92.02%-2.32M
-237.60%-1.88M
---1.07M
---1.55M
---29.11M
---555.83K
Net income from continuous operations
-1.37%-1.68M
9.36%-2.46M
11.29%-2.20M
45.91%-1.35M
40.90%-1.65M
28.99%-2.72M
5.02%-2.48M
-7.44%-2.50M
-49.11%-2.80M
-256.66%-3.83M
-68.14%-2.61M
92.02%-2.32M
-237.60%-1.88M
---1.07M
---1.55M
---29.11M
---555.83K
Net income attributable to controlling interests
-1.37%-1.68M
9.36%-2.46M
11.29%-2.20M
45.91%-1.35M
40.90%-1.65M
28.99%-2.72M
5.02%-2.48M
-7.44%-2.50M
-49.11%-2.80M
-256.66%-3.83M
-68.14%-2.61M
92.02%-2.32M
78.59%-1.88M
---1.07M
---1.55M
---29.11M
---8.76M
Preferred share dividend
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--8.21M
Net income attributable to common shareholders
-1.37%-1.68M
9.36%-2.46M
11.29%-2.20M
45.91%-1.35M
40.90%-1.65M
28.99%-2.72M
5.02%-2.48M
-7.44%-2.50M
-49.11%-2.80M
-256.66%-3.83M
-68.14%-2.61M
92.02%-2.32M
78.59%-1.88M
---1.07M
---1.55M
---29.11M
---8.76M
Basic earnings per share
36.01%-0.04
14.74%-0.09
12.32%-0.08
46.54%-0.05
41.58%-0.06
29.42%-0.11
13.23%-0.10
2.14%-0.10
-35.79%-0.11
-224.85%-0.15
-67.63%-0.11
91.94%-0.10
78.66%-0.08
---0.05
---0.07
---1.23
---0.38
Diluted earnings per share
36.01%-0.04
14.74%-0.09
12.32%-0.08
46.54%-0.05
41.58%-0.06
29.42%-0.11
13.23%-0.10
2.14%-0.10
-35.79%-0.11
-224.85%-0.15
-67.63%-0.11
91.94%-0.10
78.66%-0.08
---0.05
---0.07
---1.23
---0.38
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
